Multiple testing in the 'Canakinumab in atherosclerosis' trial: correction required?
作者信息
Guzelant Gul, Ongen Zeki
机构信息
Department of Internal Medicine, Division of Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey.
Department of Cardiology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey.
出版信息
Clin Exp Rheumatol. 2017 May-Jun;35 Suppl 104(2):24. Epub 2017 Apr 27.
PMID:28516876
Abstract
摘要
相似文献
1
Multiple testing in the 'Canakinumab in atherosclerosis' trial: correction required?“卡那单抗治疗动脉粥样硬化”试验中的多重检验：是否需要校正？
Clin Exp Rheumatol. 2017 May-Jun;35 Suppl 104(2):24. Epub 2017 Apr 27.
2
Canakinumab for secondary prevention of atherosclerotic disease.卡那奴单抗用于动脉粥样硬化疾病的二级预防。
Expert Opin Biol Ther. 2018 Feb;18(2):215-220. doi: 10.1080/14712598.2018.1420776. Epub 2017 Dec 27.
3
Canakinumab for Atherosclerotic Disease.卡那单抗用于治疗动脉粥样硬化疾病。
N Engl J Med. 2018 Jan 11;378(2):199-200. doi: 10.1056/NEJMc1714635.
4
Canakinumab and Lung Cancer: Intriguing, but Is It Real?卡那单抗与肺癌：耐人寻味，但确有其事？
Oncologist. 2018 Jun;23(6):637-638. doi: 10.1634/theoncologist.2018-0116. Epub 2018 Apr 17.
5
One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1β.一个靶点两种不同结合模式：对 gevokizumab 和 canakinumab 与白细胞介素-1β相互作用的结构见解。
J Mol Biol. 2013 Jan 9;425(1):94-111. doi: 10.1016/j.jmb.2012.09.021. Epub 2012 Oct 3.
6
Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).白细胞介素-1β 抑制与复发性心血管事件的预防：卡那奴单抗抗炎血栓结局研究（CANTOS）的原理和设计。
Am Heart J. 2011 Oct;162(4):597-605. doi: 10.1016/j.ahj.2011.06.012. Epub 2011 Sep 14.
7
Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome.在 Schnitzler 综合征的 9 个月试验中，单克隆抗白细胞介素-1β抗体 canakinumab 持续有效。
Ann Rheum Dis. 2013 Oct;72(10):1634-8. doi: 10.1136/annrheumdis-2012-202192. Epub 2012 Oct 19.
8
Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis.卡那单抗在全身型幼年特发性关节炎患者中的药代动力学和药效学
J Clin Pharmacol. 2016 Dec;56(12):1516-1527. doi: 10.1002/jcph.754. Epub 2016 Jun 8.
9
Canakinumab: in patients with cryopyrin-associated periodic syndromes.卡那奴单抗：用于治疗冷球蛋白血症相关周期性综合征患者。
BioDrugs. 2012 Feb 1;26(1):53-9. doi: 10.2165/11208450-000000000-00000.
10
Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis.卡那单抗治疗痛风性关节炎患者的药代动力学和药效学特征。
J Clin Pharmacol. 2013 Dec;53(12):1240-51. doi: 10.1002/jcph.162. Epub 2013 Sep 30.
Zotero 插件